National Institute for Health and Clinical Excellence (NICE)
NICE draft guidance recommends sapropterin for children with rare inherited metabolic condition phenylketonuria
NICE has today (25 February 2021) issued draft guidance for public consultation which recommends sapropterin (also called Kuvan and made by BioMarin) for treating phenylketonuria (PKU) in children aged up to 18.
PKU is usually diagnosed in children and is a rare, inherited, chronic and life-long condition. It is caused by the lack of an enzyme which breaks down phenylalanine, a compound which occurs naturally in protein-rich foods such as milk, eggs and meat. Phenylalanine in high concentrations is toxic to the central nervous system. If the condition isn’t managed phenylalanine accumulates in the blood and can cause irreversible brain damage in babies and children and affect brain function in adults.
Current management for PKU is a lifetime adherence to a severely protein-restricted diet which cuts out most natural proteins (such as meat, fish, eggs, cheese, pulses, seeds, flour, bread and pasta), together with dietary supplements. Sapropterin is offered alongside a protein-restricted diet. The aim of treatment with sapropterin is to reduce blood phenylalanine levels and relax the restrictions on the diet as much as possible.
The clinical trial evidence shows that sapropterin reduces blood phenylalanine levels in people with PKU but it is uncertain how well it works because there is only short-term clinical trial evidence.
The committee acknowledged that sapropterin could prevent long-term irreversible brain damage in children because childhood is most critical period for brain development. However, they were uncertain to what extent sapropterin reduces reliance on a protein-restricted diet.
There were limitations with the economic analyses presented, which made it difficult to estimate the cost effectiveness of sapropterin. However, when accounting for the benefits and cost of the treatment the committee concluded that sapropterin in children is likely to be within the range NICE considers an effective use of NHS resources.
Adults, whose neurological development is complete, are not susceptible to irreversible brain damage caused by uncontrolled phenylalanine levels in the same way as children. Adults also need a higher dose of sapropterin than children. These factors, taken together with uncertainties about the extent to which it reduces reliance on a protein-restricted diet, the absence of data on whether sapropterin might improve quality-of-life, and limitations of the cost effectiveness analyses presented meant that sapropterin in adults was not considered to be a cost-effective use of NHS resources.
The committee also acknowledged that PKU is a particular concern if poorly controlled before and during pregnancy because it can be harmful to the unborn child. However, a lack of evidence meant that the committee was unable to make a recommendation on the use of sapropterin for pregnant women and women of childbearing age. The committee would like to see further evidence in this population to reconsider its conclusion at its next meeting.
Meindert Boysen, deputy chief executive and director of the Centre for Health Technology Assessment at NICE, said:
“Sapropterin allows patients to manage their condition more easily, reduces symptoms, and provides peace of mind about blood phenylalanine levels. Even though the evidence for a substantial reduction in the protein-restricted diet is lacking, when combined with concerns for long-term irreversible brain damage and impact on quality of life, it can be recommended as an option in children, alongside a protein-restricted diet.
“Because of the weight-based dosing, and without the effect assumed for children, there is very limited scope for the drug to be considered cost-effective in adults. One exception is its use to prevent harm to the unborn child in women with PKU who are pregnant or trying to conceive. We urge the company to work with us to try to find constructive solutions to the uncertainties highlighted in the draft guidance, particularly where it concerns this group.”
There are currently around 2,250 people with PKU in England. The company estimates that approximately 75 children aged under 18 with PKU would be eligible for treatment with sapropterin out of a total eligible population of around 308 people.
The closing date for comments on the draft guidance is 16 March 2021. The committee will meet to consider the responses to the consultation on 7 April 2021.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
NICE recommends range of effective treatments for people with chronic primary pain and calls on healthcare professionals to recognise and treat a person’s pain as valid and unique to them07/04/2021 13:20:00
People with chronic primary pain should be offered a range of treatments to help them manage their condition, NICE has said in its guideline on the assessment and management of chronic pain published today (7 April)
Starting with the end in mind - the Innovative Licensing and Access Pathway29/03/2021 16:15:00
Blog posted by: Nick Crabb and Meindert Boysen, NICE's members on the ILAP Steering Group, 26 March 2021.
NICE publishes single guideline for managing COVID-1924/03/2021 11:15:00
One year on from the first national lockdown, NICE yesterday (23 March) published a single guideline for the management of COVID-19 in children and adults.
Triple therapy recommended by NICE for patients with multiple myeloma23/03/2021 14:15:00
The therapy has been recommended after a confidential discount was agreed between NHS England and the drug manufacturer Amgen.
Unpaid carers should be offered advice and support, says NICE19/03/2021 15:25:00
NICE has today published a new quality standard aimed at improving the wellbeing of adults who provide unpaid care for people over 16 years old
Ovarian cancer patients to have NICE-approved drug combination option on Cancer Drugs Fund19/03/2021 12:20:00
A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer will now be available on the Cancer Drugs Fund (CDF), following its approval by NICE in draft guidance published today
Chemotherapy-free treatment option to be offered to patients with England’s most common leukaemia19/03/2021 11:15:00
Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.
NICE approves life-changing gene therapy for treating spinal muscular atrophy09/03/2021 16:15:00
A new and potentially curative one-off gene therapy for babies with the rare genetic disorder spinal muscular atrophy (SMA) is set to become the most expensive treatment ever approved by NICE.
Children and young people need accurate, accessible information about their healthcare05/03/2021 11:25:00
New draft guidance from NICE published today recommends ensuring children and young people are fully informed about their health so that they are empowered to take an active role in their healthcare